TILT Biotherapeutics Ltd[Grants and Funding] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2021	2
2022	1
2024	0

Page 1

Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1.

Havunen R, Kalliokoski R, Siurala M, Sorsa S, Santos JM, Cervera-Carrascon V, Anttila M, Hemminki A. Havunen R, et al. Cells. 2021 Jan 27;10(2):246. doi: 10.3390/cells10020246. Cells. 2021. PMID: 33513935 Free PMC article.

Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.

Santos J, Heiniö C, Quixabeira D, Zafar S, Clubb J, Pakola S, Cervera-Carrascon V, Havunen R, Kanerva A, Hemminki A. Santos J, et al. Cells. 2021 Apr 22;10(5):978. doi: 10.3390/cells10050978. Cells. 2021. PMID: 33922052 Free PMC article.

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers.

Heiniö C, Clubb J, Kudling T, Quixabeira D, Cervera-Carrascon V, Havunen R, Grönberg-Vähä-Koskela S, Santos JM, Tapper J, Kanerva A, Hemminki A. Heiniö C, et al. Diseases. 2022 Aug 8;10(3):52. doi: 10.3390/diseases10030052. Diseases. 2022. PMID: 35997357 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year